Diagnostic and pathogenetic significance of apolipoprotein disorders in patients with alcoholic fatty liver
Abstract
Background/Aim. Alcohol is the most common cause of fatty liver. Alcohol metabolism takes place in the liver by alcohol dehydrogenase, to toxic acetaldehyde, with fatty acids accumulation in the liver as a consequence. By daily intake of the amount greater than 80 g/day for men and 20 g for women, there is the risk for developing the alcoholic fatty liver (AFLD). The aim of this study was to determine the profile of atherogenic factors in plasma of patients with AFLD compared to patients with non-alcoholic fatty liver (NAFLD) and determine its diagnostic significance. Methods. The study included 74 patients with AFLD who consumed alcoholic beverages daily in large quantities and over 80 g [for men: 3–4 units (U) of alcohol and for women 2–3 U]; the control group consisted of 70 patients with NAFLD verified with ultrasound. A total holesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C) and apoliporoteins (ApoA1 and ApoB) were determined and the ratios TC/HDL-C, ApoB/ApoA1 and LDL-C/HDL-C were calculated. Results. The study included two group: 74 AFLD patients (21% of women and 79% of men), mean age 42.65 ± 9.73 years, who consumed alcoholic beverages daily in the amounts of 80 g, or greter, during the average 2.31 ± 0.96 years and 70 patients with NAFLD (37.5% of women and 63.5% of men) with the average 41.3 ± 4.1 years. There was no significant difference in gender distribution and the average age between the examined groups. Higher values of TG – 9.94 ± 2.94 mmol/L, TC 14.53 ± 2.81 mmol/L, LDL-C 8.57 ± 2.15 mmol/L and ApoB 3.97 ± 0.28 g/L and lower values of HDL-C 0.43 ± 0.11 mmol/L, Apo A1 0.49 ± 0.09 g/L and ApoB/ApoA1 ratio 2.43 ± 1.27 were registered in the AFLD group compared to those registered in the NAFLD group, (TG 8.74 ± 2.54 mmol/L TC 9.87 ± 2.36, LDL-C 6.72 ± 1.98 mmol/L, Apo B 2.38 ± 0.16 g/L, HDL-C 0.78 ± 0.09 mmol/L, Apo A1 0.98 ± 0.04 g/L and ApoB/ApoA1 ratio 7.81±1.42). There were no differences in albumin concentration, international normalized ratio (INR) and values of haemoglobin and haematocrit between the groups. Conclusion. Lipids and the ApoB/ApoA1 ratio, besides markers of hepatocelular damage, can serve as a diagnostic criteria for the presence of AFLD, and as a better indicator of atherogenic risk.
References
Mandayam S, Jamal M, Morgan TR. Epidemiology of Alcoholic Liver Disease. Semin Liver Dis 2004; 24(3): 217−32.
Alcohol use and alcohol use disorders in the United States: Main findings from the 2001-2002 National Epidemiologic Survey on Alcohol Use and Related Conditions (NESARC). Bethesda, Md: National Epidemiologic Survey on Alcohol Use and Related Conditions (NESARC); National Institutes of Health (U.S.); National Institute on Alcohol Abuse and Alco-holism (U.S.); CSR. 2006. Available from: http://www.ginasthma.org
Yoon YH, Yi HY. Surveillance report #75: Liver Cirrhosis Mortality in the United States, 1970-2003. Bethesda, MD: Na-tional Institute on Alcohol Abuse and Alcoholism; 2006.
Sougioultzis S, Dalakas E, Hayes PC, Plevris JN. Alcoholic hepati-tis: From pathogenesis to treatment. Curr Med Res Opin 2005; 21(9): 1337−46.
Lieber CS. New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments. Curr Gastroenterol Rep 2004; 6(1): 60−5.
Kamper-Jorgensen M, Gronbaek M, Tolstrup J, Becker U. Alcohol and cirrhosis: Dose-response or threshold effect. J Hepatol 2004; 41(1): 25−30.
Pessione F, Ramond M, Peters L, Pham B, Batel P, Rueff B, et al. Five-year survival predictive factors in patients with excessive alcohol intake and cirrhosis. Effect of alcoholic hepatitis, smoking and abstinence. Liver Int 2003; 23(1): 45−53.
Mendez-Sanchez N, Meda-Valdes P, Uribe M. Alcoholic liver dis-ease. An update. Ann Hepatol 2005; 4(1): 32−42.
Leevy CM, Moroianu SA. Nutritional aspects of alcoholic liver disease. Clin Liver Dis 2005; 9(1): 67−81.
Lefkowitch JH. Morphology of alcoholic liver disease. Clin Liver Dis 2005; 9(1): 37−53.
Barrio E, Tome S, Rodriguez I, Gude F, Sanchez-Leira J, Perez-Becerra E, et al. Liver Disease in Heavy Drinkers With and Without Alcohol Withdrawal Syndrome. Alcohol Clin Exp Res 2004; 28(1): 131−6.
Aertgeerts B, Buntinx F, Kester A. The value of the CAGE in screening for alcohol abuse and alcohol dependence in general clinical populations: A diagnostic meta-analysis. J Clin Epi-demiol 2004; 57(1): 30−9.
Nyblom H. High AST/ALT ratio may indicate advanced alco-holic liver disease rather than heavy drinking. Alcohol Alcohol 2004; 39(4): 336−9.
Hannuksela ML, Liisanantti MK, Nissinen AE, Savolainen MJ. Bi-ochemical markers of alcoholism. Clin Chem Lab Med 2007; 45(8): 953−61.
Anttila P, Jarvi K, Latvala J, Romppanen J, Punnonen K, Niemela O. Biomarkers of alcohol consumption in patients classified ac-cording to the degree of liver disease severity. Scand J Clin Lab Invest 2005; 65(2): 141−51.
Niemela O. Biomarkers in alcoholism. Clin Chim Acta 2007; 377(1−2): 39−49.
Shiffman RN, Shekelle P, Overhage JM, Slutsky J, Grimshaw J, Desh-pande AM. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardi-zation. Ann Intern Med 2003; 139(6): 493−8.
Levitsky J, Mailliard ME. Diagnosis and Therapy of Alcoholic Liver Disease. Semin Liver Dis 2004; 24(3): 233−47.
Aalto M, Seppä K. Use of laboratory markers and the audit questionnaire by primary care physicians to detect alcohol abuse by patients. Alcohol Alcohol 2005; 40(6): 520−3.
Alte D, Luedemann J, Rose HJ, John U. Laboratory markers car-bohydrate-deficient transferrin, gamma-glutamyltransferase, and mean corpuscular volume are not useful as screening tools for high-risk drinking in the general population: results from the Study of Health in Pomerania (SHIP). Alcohol Clin Exp Res 2004; 28(6): 931−40.
Chen J. Combining carbohydrate-deficient transferrin and gamma-glutamyltransferase to increase diagnostic accuracy for problem drinking. Alcohol Alcohol 2003; 38(6): 574−82.
Trabut JB, Plat A, Thepot V, Fontaine H, Vallet-Pichard A, Nalpas B, et al. Influence of Liver Biopsy on Abstinence in Alcohol-Dependent Patients. Alcohol Alcohol 2008; 43(5): 559−63.
Helping Patients Who Drink Too Much: A Clinician's Guide. Bethesda, MD: National Institute of Health, National Institute on Alcohol Abuse and Alcoholism; 2005.
Daniel JR, Helen HH. Disorders of Lipoprotein metabolism. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, editors. Harrison's Principles of Internal Medicine. 18th ed. New York: McGrawHill Medical Publisher Division; 2012. p. 3145−61.
Rosengren A, Hawken S, Ounpuu S, Sliwa K, Zubaid M, Almahmeed WA, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364(9438): 953−62.
Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. Incremental Desrease and Events through Ag-gressive Lipid Lowering (IDEAL). Am J Cardiol 2004; 94(6): 720−4.